Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744283 · ClinicalTrials.gov registry record
Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
A clinical trial of Fanconi Anemia, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06744283 is a study of Fanconi Anemia that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06744283, a study of Fanconi Anemia, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal organs. Young adults have a much higher risk of cancer. To screen for these cancers, people with FA may need to pursue many visits with different doctors. This constant need for cancer screening may cause anxiety for people with FA. Objective: To learn more about anxiety related to cancer screenings in people with FA. Eligibility: Adults aged 18 years and older with FA. They must also be enrolled in FACSS. FACSS is a study that screens people with FA for cancer every year. Design: All data gathered for this study will occur during routine FACSS visits. No other visits are needed. An observer will be in the room during participants FACSS visits. The observer and participant will have a polite introduction. After that, the observer will not interact with participants in any way. The observer will note details about the participants, such as: * Body language. * Worries about screening. * Comments that suggest anxiety or depression. * Clinical environment, such as d(SqrRoot)(Copyright)cor and temperature. * Accessibility issues. These can include lights and noises as well as ease of traveling around the clinic center. * Evidence of social support, such as engaging in the FA community. * Challenges they ve had in FACSS. * Their motivation to participate in FACSS. * Relationship dynamics among clinic staff, participants, and their care partners. Data will also be collected from FACSS visit notes dating back to December 2024 and from participants medical records.
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2027-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744283
The ClinicalTrials.gov registry entry for NCT06744283 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (94% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fanconi Anemia appearing as the primary indexed condition, and to 0 interventions.
NCT06744283 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06744283 about?
NCT06744283 is a clinical study titled "Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia". Background: Fanconi anemia (FA) is a rare, inherited cancer syndrome. FA causes a range of physical issues. Children with FA may have abnormal features; these may include a small head and eyes and issues with their internal organs. Young adults have a much higher risk of cancer. To screen for these...
What is the current status of trial NCT06744283?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2026-03-26. Estimated completion is 2027-01-30.
What conditions does trial NCT06744283 study?
This clinical trial studies the following conditions: Fanconi Anemia.
Who is sponsoring clinical trial NCT06744283?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744283 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fanconi Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
RECRUITING · Phase 1
-
Role of Acetaldehyde in the Development of Oral Cancer
RECRUITING · NA
-
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
RECRUITING
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
Cancer in Inherited Bone Marrow Failure Syndromes
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.